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Twenty-five years have passed since the first lung transplant
was performed at the Instituto do Corac¸ão (INCOR) do Hospital
das Clínicas da Faculdade de Medicina da Universidade de
São Paulo. On October 16th, 1990, a 26-year-old woman with
severe pulmonary fibrosis and secondary pulmonary hyper-
tension underwent a single left lung transplant but only
survived for 12 days, dying due to sepsis and diffuse alveolar
damage. This occurred several months after the first and
second (1) lung transplants in Brazil and seven years after the
first in the world, which had been performed by Dr. Cooper
in Toronto (2). Over a five-year period, nine more cases were
performed, with the longest post-operative survival being
4 years. Despite the dedication of all the personnel involved
with the program at that time, seven patients were never
discharged due to acute respiratory failure and infection.
At present, primary graft dysfunction remains a complication
of transplant procedures, but in 1995, it seemed an almost
insurmountable barrier. Despite the strong desire to continue
performing this procedure, the group was not adequately
prepared to continue in this field and the program was
discontinued.
In parallel, pulmonologists and surgeons sought training at
other lung transplant centers and research in the field was
initiated at our laboratory in the Medical School. Because
bronchial healing remained a problem in clinical cases, it was
chosen as a starting point for research. Using animal models
of bronchial anastomosis and lung transplant as well as an
established methodology for the evaluation of airway mucous
clearance, the effect of immunosuppressive drugs was tested.
Cyclosporin (3-5), Prednisone (6,7), Micophenolate (8) and
combined therapies, including Tacrolimus (9,10), were tested
and all drugs had a negative impact on mucous clearance.
On August 9th 2000, a single right lung transplant was
performed on a 32-year-old male with silicosis. The post-
operative period was uneventful and the patient is still alive
fifteen years later. The main problems concerning intra-
operative care, post-operative care and immunosuppression
seemed to be solved. However, in the following three years
we performed ten more procedures, of which only two pa-
tients survived for more than one year. Although only two
patients of this period are still alive, the low survival rate
indicated that there was still something lacking. At that time,
the current knowledge and infrastructure were considered
sufficient, but it was clear that unless a dedicated team was
established, we could not proceed in this field.
In 2003, a multi-professional and multi-disciplinary team
was formed that included pulmonologists, surgeons, infec-
tologists, nurses, physiotherapists, nutritionists, social work-
ers and psychologists. We established a routine of morning
rounds in ICU and on the wards; assessment meetings;
scientific meetings and journal clubs. Based on candidate
selection criteria established by the International Society for
Heart and Lung Transplantation, patients considered for LTx
were assessed and visited by all members of the lung
transplant team. Inclusion on a waiting list was possible only
upon the agreement of all members of the staff.
Since then, almost 250 procedures have been performed,
including some landmark procedures: the first bilateral proce-
dure in 2003, the first pediatric transplant in 2006, the first split
transplant in 2011 and the first transplant using the ex vivo lung
perfusion (EVLP) technique in 2012. However, some problems
persisted. Initially, simple preoperative monitoring and patient
positioning were problematic and each transplant presented
individualized challenges, illustrating the difficulties inherent in
establishing routines in the operating room.
However, over time, the program has achieved consistently
satisfactory results and survival in line with international rates
(Figure 1). For diseases such as cystic fibrosis, the survival to
the end of the first year is over 90%, even higher than the
ISHLT Resistries (11). Approximately 35 procedures are per-
formed annually in the State of São Paulo - a modest number
compared to the number of patients on the waiting list, which
impacts on the mortality rate of patients on the list. The main
reason for the low number of transplants performed is the low
success rate of lungs obtained from multiorgan donors. It is
estimated that only 5% of available lungs are used, a very low
frequency compared to the average rate of 15% reported by the
UNOS (12). The main reason for the low utilization is the
quality of the available lungs, which are rejected more than
50% of the time due to infection or inadequate management
resulting in loss of lung function (13).
Improving the quality of available donor lungs seemed to
be the best solution for increasing the number of transplants.
Thus, the first report on the reconditioning of initially
rejected donor lungs by ex vivo perfusion (14) presented a
solution for this problem. In 2007 we began preparations for
EVLP via training courses and experimental studies with
lungs rejected for transplantation. We initially sought to
establish our methodology (15,16), then tested lung pre-
servation solutions (17) and static or continuous topical
preservation methodologies (18). This prepared us to per-
form the first lung transplantation using EVLP in Brazil in
2012. Three years after the procedure, the first patient is
doing well. However, the cost and quality of using EVLPDOI: 10.6061/clinics/2015(12)02
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donor tissue in our country, and as a result, other transplants
have not been performed with this technique. New research
has been implemented in this area that incorporated the use
of broad spectrum antibiotics during EVLP (19) and in
trachea transplantation (20,21).
Two important issues remaining are the training of
personnel and international recognition. All staff members
were trained in our institution and completed the training in
transplant centers in North America or Europe. The Ministry
of Health has certified InCor for medical residency in pul-
monary and surgical transplantation, as well as two years of
training in a clinical or surgical fellowship in lung transplanta-
tion certified by the Ministry of Education. We are inter-
nationally recognized as a part of the ISHLT registry and we
actively participate in international congresses as members of
the society and through the submission of scientific papers.
Institutional support is fundamental for the maintenance of
staff and we were supported without fail throughout the
formation of the transplant group. Although the number of
transplants performed every month remains small, the need of
these patients for care is intense. Thus, maintaining a profes-
sional team on a full-time basis will only be feasible with
professional development and salary adjustments. In 2013, the
Transplant Center Unit of InCor was created, which relies on a
24/7 nursing team fully dedicated to procuring thoracic organs
and mediating and enhancing the work of the transplant teams,
resulting in the realization of 98 transplants in 2014, including
adult and pediatric heart transplants and lung transplants.
The road traveled thus far has enabled the formation of an
accomplished group and national leadership in this area. It is
essential that the foundations of our group are the same as
those of universities: care, teaching and research. We believe
that we have achieved these goals, but much remains to be
accomplished in this field.
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Figure 1 - Kaplan-Meier Survival Curve of LTx patients. One year
survival: 65.6%, Five years survival: 55.3% and Ten years survival:
43.7%.
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